HomeCompareADMS vs MCD

ADMS vs MCD: Dividend Comparison 2026

ADMS yields 24.33% · MCD yields 2.34%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ADMS wins by $17.2K in total portfolio value
10 years
ADMS
ADMS
● Live price
24.33%
Share price
$8.22
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$94.9K
Annual income
$10,445.94
Full ADMS calculator →
MCD
McDonald's Corporation
● Live price
2.34%
Share price
$310.79
Annual div
$7.26
5Y div CAGR
42.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$77.7K
Annual income
$25,833.37
Full MCD calculator →

Portfolio growth — ADMS vs MCD

📍 ADMS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodADMSMCD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ADMS + MCD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ADMS pays
MCD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ADMS
Annual income on $10K today (after 15% tax)
$2,068.13/yr
After 10yr DRIP, annual income (after tax)
$8,879.05/yr
MCD
Annual income on $10K today (after 15% tax)
$198.56/yr
After 10yr DRIP, annual income (after tax)
$21,958.36/yr
At 15% tax rate, MCD beats the other by $13,079.32/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ADMS + MCD for your $10,000?

ADMS: 50%MCD: 50%
100% MCD50/50100% ADMS
Portfolio after 10yr
$86.3K
Annual income
$18,139.66/yr
Blended yield
21.01%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MCD right now

ADMS
Analyst Ratings
6
Buy
7
Hold
2
Sell
Consensus: Hold
MCD
Analyst Ratings
37
Buy
23
Hold
1
Sell
Consensus: Buy
Price Target
$351.76
+13.2% upside vs current
Range: $320.00 — $385.00
Altman Z
4.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ADMS buys
0
MCD buys
0
No recent congressional trades found for ADMS or MCD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricADMSMCD
Forward yield24.33%2.34%
Annual dividend / share$2.00$7.26
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%42.3%
Portfolio after 10y$94.9K$77.7K
Annual income after 10y$10,445.94$25,833.37
Total dividends collected$59.3K$57.7K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary
Analyst consensusHoldBuy

Year-by-year: ADMS vs MCD ($10,000, DRIP)

YearADMS PortfolioADMS Income/yrMCD PortfolioMCD Income/yrGap
1← crossover$13,133$2,433.09$10,812$332.41+$2.3KADMS
2$17,039$2,986.35$11,819$488.02+$5.2KADMS
3$21,852$3,621.00$13,111$724.37+$8.7KADMS
4$27,722$4,340.18$14,832$1,091.05+$12.9KADMS
5$34,809$5,145.80$17,219$1,675.85+$17.6KADMS
6$43,284$6,038.47$20,688$2,641.85+$22.6KADMS
7$53,331$7,017.47$25,990$4,309.70+$27.3KADMS
8$65,145$8,080.76$34,590$7,351.77+$30.6KADMS
9$78,930$9,225.06$49,535$13,285.25+$29.4KADMS
10$94,901$10,445.94$77,746$25,833.37+$17.2KADMS

ADMS vs MCD: Complete Analysis 2026

ADMSStock

Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. It is also developing ADS-5102 that is in Phase III clinical study to treat walking impairment in patients with multiple sclerosis and other indications; and ADS-4101, which has completed two Phase I studies for treating partial onset seizures in patients with epilepsy. In addition, the company offers Namzaric (memantine hydrochloride extended release and donepezil hydrochloride) capsules for the treatment of moderate to severe dementia of an Alzheimer's type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.

Full ADMS Calculator →

MCDConsumer Discretionary

McDonald's Corporation operates and franchises McDonald's restaurants in the United States and internationally. Its restaurants offer hamburgers and cheeseburgers, chicken sandwiches and nuggets, wraps, fries, salads, oatmeal, shakes, desserts, sundaes, soft serve cones, bakery items, soft drinks, coffee, and beverages and other beverages, as well as breakfast menu, including biscuit and bagel sandwiches, breakfast burritos, hotcakes, and other sandwiches. As of December 31, 2021, the company operated 40,031 restaurants. McDonald's Corporation was founded in 1940 and is headquartered in Chicago, Illinois.

Full MCD Calculator →
📬

Get this ADMS vs MCD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ADMS vs SCHDADMS vs JEPIADMS vs OADMS vs KOADMS vs MAINADMS vs YUMADMS vs QSRADMS vs SBUX

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.